The Number and Microlocalization of Tumor-associated Immune Cells Are Associated with Patient's Survival Time in Non-small Cell Lung Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 May 22

PMID 20487543

Citations 81

Authors

Fuqiang Dai

Lunxu Liu

Guowei Che

Nanbin Yu

Qiang Pu

Shangfu Zhang

Junliang Ma

Lin Ma

Zongbing You

Affiliations

Soon will be listed here.

Abstract

Background: Tumor microenvironment is composed of tumor cells, fibroblasts, endothelial cells, and infiltrating immune cells. Tumor-associated immune cells may inhibit or promote tumor growth and progression. This study was conducted to determine whether the number and microlocalization of macrophages, mature dendritic cells and cytotoxic T cells in non-small cell lung cancer are associated with patient's survival time.

Methods: Ninety-nine patients with non-small cell lung cancer (NSCLC) were included in this retrospective study. Paraffin-embedded NSCLC specimens and their clinicopathological data including up to 8-year follow-up information were used. Immunohistochemical staining for CD68 (marker for macrophages), CD83 (marker for mature dendritic cells), and CD8 (marker for cytotoxic T cells) was performed and evaluated in a blinded fashion. The numbers of immune cells in tumor islets and stroma, tumor islets, or tumor stroma were counted under a microscope. Correlation of the cell numbers and patient's survival time was analyzed using the Statistical Package for the Social Sciences (version 13.0).

Results: The numbers of macrophages, mature dendritic cells and cytotoxic T cells were significantly more in the tumor stroma than in the tumor islets. The number of macrophages in the tumor islets was positively associated with patient's survival time, whereas the number of macrophages in the tumor stroma was negatively associated with patient's survival time in both univariate and multivariate analyses. The number of mature dendritic cells in the tumor islets and stroma, tumor islets only, or tumor stroma only was positively associated with patient's survival time in a univariate analysis but not in a multivariate analysis. The number of cytotoxic T cells in the tumor islets and stroma was positively associated with patient's survival time in a univariate analysis but not in a multivariate analysis. The number of cytotoxic T cells in the tumor islets only or stroma only was not associated with patient's survival time.

Conclusions: The number of macrophages in the tumor islets or stroma is an independent predictor of survival time in NSCLC patients. Counting macrophages in the tumor islets or stroma is more useful in predicting patient's survival time than counting mature dendritic cells or cytotoxic T cells.

Citing Articles

Case Report: Lung cancer with rare cardiac and other multiple metastases.

Chen L, Zhang J, Zhang C Front Cardiovasc Med. 2024; 11:1417906.

PMID: 39328239 PMC: 11424542. DOI: 10.3389/fcvm.2024.1417906.

Density of tertiary lymphoid structures and their correlation with prognosis in non-small cell lung cancer.

Xin S, Wen S, He P, Zhao Y, Zhao H Front Immunol. 2024; 15:1423775.

PMID: 39192984 PMC: 11347756. DOI: 10.3389/fimmu.2024.1423775.

The GJB3 correlates with the prognosis, immune cell infiltration, and therapeutic responses in lung adenocarcinoma.

Dou R, Liu R, Su P, Yu X, Xu Y Open Med (Wars). 2024; 19(1):20240974.

PMID: 39135979 PMC: 11317640. DOI: 10.1515/med-2024-0974.

Pan-Cancer Analysis Identifies BCLAF1 as a Potential Biomarker for Renal Cell Carcinoma.

Yan H, Wu X, Li H, Yu Z, Jin X Biochem Genet. 2024; .

PMID: 38573525 DOI: 10.1007/s10528-024-10773-x.

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.

Raskova Kafkova L, Mierzwicka J, Chakraborty P, Jakubec P, Fischer O, Skarda J Front Immunol. 2024; 15:1342086.

PMID: 38384472 PMC: 10879685. DOI: 10.3389/fimmu.2024.1342086.

References

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T . Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008; 113(6):1387-95. DOI: 10.1002/cncr.23712. View

van Cruijsen H, Ruiz M, van der Valk P, de Gruijl T, Giaccone G . Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer. 2009; 9:180. PMC: 2705377. DOI: 10.1186/1471-2407-9-180. View

Ueda K, Kaneda Y, Sakano H, Tanaka T, Hayashi M, Li T . Independent predictive value of the overall number of metastatic N1 and N2 stations in lung cancer. Jpn J Thorac Cardiovasc Surg. 2003; 51(7):297-301. DOI: 10.1007/BF02719381. View

Lin A, Schildknecht A, Nguyen L, Ohashi P . Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett. 2009; 127(2):77-84. DOI: 10.1016/j.imlet.2009.09.003. View

Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L . The origin and function of tumor-associated macrophages. Immunol Today. 1992; 13(7):265-70. DOI: 10.1016/0167-5699(92)90008-U. View

Welsh T, Green R, Richardson D, Waller D, OByrne K, Bradding P . Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005; 23(35):8959-67. DOI: 10.1200/JCO.2005.01.4910. View

Mantovani A, Sica A, Locati M . Macrophage polarization comes of age. Immunity. 2005; 23(4):344-6. DOI: 10.1016/j.immuni.2005.10.001. View

Toomey D, Smyth G, Condron C, Kelly J, Kay E, Conroy R . Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer. 2002; 103(3):408-12. DOI: 10.1002/ijc.10836. View

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

10.

Chen J, Lin Y, Yao P, Yuan A, Chen H, Shun C . Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 2004; 23(5):953-64. DOI: 10.1200/JCO.2005.12.172. View

11.

Mantovani A, Sica A, Locati M . New vistas on macrophage differentiation and activation. Eur J Immunol. 2006; 37(1):14-6. DOI: 10.1002/eji.200636910. View

12.

Fukui T, Mori S, Yokoi K, Mitsudomi T . Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol. 2007; 1(2):120-5. View

13.

Bergeron A, El-Hage F, Kambouchner M, Lecossier D, Tazi A . Characterisation of dendritic cell subsets in lung cancer micro-environments. Eur Respir J. 2006; 28(6):1170-7. DOI: 10.1183/09031936.06.00114205. View

14.

Loose D, Van de Wiele C . The immune system and cancer. Cancer Biother Radiopharm. 2009; 24(3):369-76. DOI: 10.1089/cbr.2008.0593. View

15.

Kim D, Min H, Lee K, Kim Y, Oh D, Jeon Y . High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer. 2008; 98(6):1118-24. PMC: 2275476. DOI: 10.1038/sj.bjc.6604256. View

16.

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

17.

Chen J, Yao P, Yuan A, Hong T, Shun C, Kuo M . Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003; 9(2):729-37. View

18.

Ohri C, Shikotra A, Green R, Waller D, Bradding P . Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009; 33(1):118-26. DOI: 10.1183/09031936.00065708. View

19.

Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, Jacquet C, Yoneda K . CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med. 1996; 184(2):695-706. PMC: 2192705. DOI: 10.1084/jem.184.2.695. View

20.

Kretschmer B, Luthje K, Schneider S, Fleischer B, Breloer M . Engagement of CD83 on B cells modulates B cell function in vivo. J Immunol. 2009; 182(5):2827-34. DOI: 10.4049/jimmunol.0803153. View